ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
21 announcements with these filters
Indo US Bio-Tech Ltd reported revenue from operations of ₹15 Cr (-51.3% YoY) and a net loss of ₹3.7 Cr for Q2 FY27.
Indo Us Bio-Tech has intimated that its board will meet on 30 October 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. The notice is advance intimation only, with no results yet reported.
Indo Us Bio-Tech disclosed promoter invitations to attend China's 140th Canton Fair. The filing states no financial value or business commitment.
Indo Us Bio-Tech Ltd filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the quarter ended September 30, 2026.
Indo Us Bio-Tech Limited held its 22nd Annual General Meeting on September 30, 2026. The filing provides a gist of the meeting's proceedings and agenda items.
Indo Us Bio-Tech Ltd submitted its Annual Report for FY 2025-2026. The 22nd Annual General Meeting is scheduled for September 30, 2026.
Indo Us Bio-Tech Limited has issued a notice for its 22nd Annual General Meeting, scheduled for September 30, 2026, to be conducted via video conferencing.
Indo Us Bio-Tech Ltd announced outcomes of its board meeting, including the date for its 22nd AGM and appointment of statutory auditors.
Indo US Bio-Tech Ltd reported revenue from operations of ₹33 Cr (+7.1% YoY) and net profit of ₹3 Cr (-36.2% YoY) for Q1 FY27.
Indo Us Bio-Tech Limited announced the postal ballot results. Shareholders approved the appointment of a new director and statutory auditor.
Indo Us Bio-Tech Ltd scheduled a board meeting for August 12, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.
Indo Us Bio-Tech announced a revised effective date for board committee reconstitutions. The changes reflect director appointments and resignations effective from April 21, 2026.
Indo Us Bio-Tech Limited appointed Bhagat & Associates as Statutory Auditor following Gautam N Associates' resignation. The change aligns with administrative restructuring of audit assignments.
Indo Us Bio-Tech reconstituted its Audit, Nomination, and Stakeholders committees effective July 10, 2026. This follows the earlier appointment of Hemanshi Darsh Soni as Additional Director.
Indo Us Bio-Tech Ltd issued a Postal Ballot Notice for shareholder voting on director and auditor appointments. Voting via e-voting runs from July 5 to August 3, 2026.
Indo Us Bio-Tech Ltd's board decided to seek shareholder approval for a new independent director and statutory auditor via postal ballot. The process is scheduled for July-August 2026.
Board noted resignations and approved appointments of statutory and internal auditors. Changes are effective from June 15-16, 2026, subject to shareholder approval.
Indo US Bio-Tech Ltd reported revenue from operations of ₹26 Cr (-22.2% YoY) and net profit of ₹2 Cr (-45.9% YoY) for Q4 FY26.
Indo Us Biotech Limited reported audited financial results for the year ended March 31, 2026. Revenue from operations reached ₹110.44 Crore, marking steady growth.
Indo Us Bio-Tech Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report details governance compliance and historical regulatory observations.
Indo Us Bio-Tech scheduled a board meeting for May 29, 2026, to approve audited annual financial results. The trading window remains closed until May 30.